Free Trial

Penumbra (PEN) Stock Forecast & Price Target

Penumbra logo
$240.55 -1.99 (-0.82%)
(As of 12/23/2024 05:45 PM ET)

Penumbra - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
11

Based on 15 Wall Street analysts who have issued ratings for Penumbra in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 4 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for PEN.

Consensus Price Target

$258.00
7.25% Upside
According to the 15 analysts' twelve-month price targets for Penumbra, the average price target is $258.00. The highest price target for PEN is $323.00, while the lowest price target for PEN is $210.00. The average price target represents a forecasted upside of 7.25% from the current price of $240.55.
Get the Latest News and Ratings for PEN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Penumbra and its competitors.

Sign Up

PEN Analyst Ratings Over Time

TypeCurrent Forecast
12/25/23 to 12/24/24
1 Month Ago
11/25/23 to 11/24/24
3 Months Ago
9/26/23 to 9/25/24
1 Year Ago
12/25/22 to 12/25/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
10 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$258.00$227.92$208.00$313.00
Forecasted Upside7.25% Upside-6.91% Downside11.30% Upside21.05% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

PEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Penumbra Stock vs. The Competition

TypePenumbraMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside7.25% Upside25,625.79% Upside14.28% Upside
News Sentiment Rating
Positive News

See Recent PEN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/18/2024Truist Financial
2 of 5 stars
 Boost TargetBuy ➝ Buy$240.00 ➝ $285.00+16.37%
12/17/2024Oppenheimer
3 of 5 stars
 Initiated CoverageOutperform$275.00+11.23%
12/11/2024Citigroup
3 of 5 stars
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$220.00 ➝ $245.00-4.74%
12/11/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$190.00 ➝ $275.00+13.47%
12/9/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$260.00 ➝ $323.00+35.72%
11/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$232.00 ➝ $270.00+9.80%
A.I. Trading System Helps Some Traders Pocket $1,100 per DAY! (Ad)

What if I told you 60 seconds a day could completely change your life?

This AI-powered trading system finds high-probability option trades in less than 60 seconds a day

Click HERE to access this powerful AI Trading System
11/20/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$235.00 ➝ $250.00+5.29%
10/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$244.00 ➝ $248.00+17.43%
10/31/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
10/8/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$205.00 ➝ $222.00+14.00%
9/17/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$238.00+27.23%
9/3/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/3/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$263.00+29.99%
7/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$235.00 ➝ $210.00+9.96%
2/23/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$284.00 ➝ $250.00-4.81%
6/26/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$325.00 ➝ $376.00+13.18%
5/3/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:55 AM ET.


PEN Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Penumbra is $258.00, with a high forecast of $323.00 and a low forecast of $210.00.

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PEN shares.

According to analysts, Penumbra's stock has a predicted upside of 7.25% based on their 12-month stock forecasts.

Over the previous 90 days, Penumbra's stock had 1 upgrade by analysts.

Analysts like Penumbra less than other "medical" companies. The consensus rating score for Penumbra is 2.80 while the average consensus rating score for "medical" companies is 2.81. Learn more on how PEN compares to other companies.


This page (NYSE:PEN) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners